Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Hematological Malignancy
← New Search

Hematological Malignancy

Educational clinical summary of Hematological Malignancy for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, taking into account the specific circumstances of each patient. This content is based on current evidence and guidelines, but medical knowledge is constantly evolving. Always exercise independent clinical judgment.

This comprehensive clinical reference focuses on Acute Myeloid Leukemia (AML) as a representative and clinically significant hematological malignancy. While AML shares some general characteristics with other hematological malignancies, specific details regarding pathophysiology, diagnosis, and management are highly disease-specific.

Overview

  • Definition: Acute myeloid leukemia (AML) is a heterogeneous group of aggressive hematological malignancies characterized by the rapid, uncontrolled proliferation of abnormal, immature myeloid blasts (myeloblasts) in the bone marrow, peripheral blood, and other tissues. The diagnostic criterion typically requires ≥ 20% blasts in the bone marrow or peripheral blood, or the presence of specific recurrent genetic abnormalities (e.g., t(15;17) for APL) even with lower blast counts.
  • Epidemiology:
    • AML is primarily a disease of older adults, with the median age at diagnosis being approximately 68 years.
    • Incidence increases with age, with rates rising sharply after age 60.
    • It accounts for approximately 80% of all acute leukemias in adults.
    • Slightly more common in males than females.
    • Roughly 20,000 new cases are diagnosed annually in the United States.
  • Classification: The World Health Organization (WHO) classification (2016, updated 2022) is essential for diagnosis and risk stratification, integrating morphology, immunophenotyping, cytogenetics, and molecular genetics. Key categories include:
    • AML with recurrent genetic abnormalities: Includes various specific translocations and inversions (e.g., t(8;21), inv(16) or t(16;16), t(15;17) [APL], mutations in NPM1, CEBPA, FLT3, IDH1/2). These often predict response to therapy and prognosis.
    • AML with myelodysplasia-related changes: Arises from a pre-existing myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN), or shows MDS-like cytogenetic abnormalities. Generally has a worse prognosis.
    • Therapy-related AML (t-AML): Develops as a complication of prior cytotoxic chemotherapy or radiation therapy for other malignancies. Often associated with adverse cytogenetics.
    • AML, not otherwise specified (NOS): Cases that do not fit into the above categories, subclassified based on morphologic differentiation (e.g., AML with minimal differentiation, AML with maturation, acute myelomonocytic leukemia).
    • Myeloid sarcoma: Extramedullary proliferation of myeloid blasts.
    • Acute undifferentiated leukemia: Lacks definitive myeloid or lymphoid differentiation.

Pathophysiology

  • Mechanism: AML originates from a series of acquired genetic mutations in hematopoietic stem and progenitor cells (HSPCs). These mutations lead to:
    • Block in differentiation: Immature myeloid cells fail to mature into functional neutrophils, monocytes, erythrocytes, or platelets.
    • Uncontrolled proliferation: The abnormal cells proliferate uncontrollably, accumulating in the bone marrow and peripheral blood.
    • Apoptotic resistance: The leukemic blasts resist programmed cell death, contributing to their accumulation.
    • The accumulation of blasts in the bone marrow suppresses normal hematopoiesis, leading to bone marrow failure (anemia, neutropenia, thrombocytopenia). The blasts can also infiltrate extramedullary sites.
    • Commonly mutated genes include NPM1, FLT3, CEBPA, IDH1/2, TP53, RUNX1, ASXL1, DNMT3A, and others, often occurring in combination. The order and combination of mutations influence disease progression and prognosis (e.g., NPM1 mutations often co-occur with FLT3-ITD).
  • Risk Factors:
    • Age: Advanced age is the strongest risk factor.
    • Prior chemotherapy/radiation therapy: Especially alkylating agents and topoisomerase II inhibitors, leading to t-AML.
    • Pre-existing hematologic disorders: Myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) can transform into AML.
    • Genetic syndromes: Down syndrome, Fanconi anemia, Bloom syndrome, Ataxia-telangiectasia, Li-Fraumeni syndrome.
    • Environmental exposures: High-dose radiation exposure, certain chemicals (e.g., benzene), pesticides.
    • Smoking: Increased risk.
    • Family history: Rare, but some familial predisposition syndromes exist.
  • Protective Factors: No specific primary protective factors are widely established for AML beyond avoiding known environmental carcinogens (e.g., benzene).

Clinical Presentation

Signs and Symptoms

Symptoms typically arise from bone marrow failure (cytopenias) and/or infiltration of extramedullary sites by leukemic blasts. Onset is often acute or subacute.

  • Cardinal Features:
    • Fatigue, pallor, weakness: Due to anemia (low red blood cells).
    • Fever, recurrent infections: Due to neutropenia (low functional white blood cells). Infections can be bacterial, fungal, or viral.
    • Easy bruising, petechiae, epistaxis, gum bleeding: Due to thrombocytopenia (low platelets).
    • Weight loss, anorexia: General constitutional symptoms.
  • Early Signs: Often non-specific and mimic common infections or fatigue:
    • Mild fatigue, general malaise
    • Low-grade fevers
    • Unexplained bruising

  • Advanced Signs: Reflect more severe disease or extramedullary involvement:

    • Hepatosplenomegaly: Enlargement of liver and spleen due to blast infiltration.
    • Lymphadenopathy: Enlarged lymph nodes (less common in AML than ALL).
    • Gingival hypertrophy: Swelling of gums, particularly in acute monocytic leukemia (M5 subtype).
    • Leukemia cutis: Skin nodules or lesions due to blast infiltration.
    • Central Nervous System (CNS) involvement: Headaches, visual changes, cranial nerve palsies (rare at diagnosis, more common in relapsed/refractory disease or specific subtypes like M4/M5).
    • Leukostasis: Extremely high WBC count (typically >100,000/µL) leading to symptomatic sludging in microvasculature, causing dyspnea, confusion, visual changes. This is a medical emergency.
    • Disseminated Intravascular Coagulation (DIC): Especially common in acute promyelocytic leukemia (APL, M3 subtype), leading to both bleeding and thrombotic complications.

  • Atypical Presentations:

    • Unexplained persistent fever (fever of unknown origin).
    • Single-lineage cytopenia initially (e.g., isolated severe anemia).
    • Bone or joint pain, especially in children, mimicking arthritis.
    • Chloroma (myeloid sarcoma): A localized tumor of leukemic cells, potentially anywhere in the body (e.g., orbit, spinal cord, skin), sometimes preceding bone marrow involvement.

Physical Examination

Findings reflect the underlying cytopenias and blast infiltration.

  • Inspection:
    • Pallor: Indicative of anemia.
    • Petechiae/Ecchymoses: Small pinpoint hemorrhages and larger bruises, indicative of thrombocytopenia.
    • Gingival hypertrophy: Swelling and bleeding of gums.
    • Skin lesions (leukemia cutis): Erythematous, violaceous, or hyperpigmented papules, nodules, or plaques.
    • Signs of infection: Cellulitis, abscesses, oral candidiasis, perirectal tenderness.
    • Signs of leukostasis: Respiratory distress, altered mental status, papilledema.
  • Palpation:
    • Hepatosplenomegaly: Enlarged liver and/or spleen.
    • Lymphadenopathy: Palpable lymph nodes (less prominent than in lymphoid malignancies).
    • Sternal tenderness: Due to marrow expansion.
    • Testicular enlargement: Unilateral or bilateral (rare, but can occur).
  • Special Tests:
    • Funduscopic examination: To detect retinal hemorrhages or leukemic infiltrates, especially if CNS symptoms are present or WBC count is very high.
    • Neurological examination: To assess for signs of CNS involvement (cranial nerve palsies, altered mental status, motor/sensory deficits).

Diagnostic Approach

The diagnosis of AML requires a combination of laboratory tests and pathological evaluation of bone marrow and peripheral blood.

History Taking

Crucial for understanding the clinical context and identifying risk factors.

  • Key Questions:
    • Symptom onset and progression: Duration of fatigue, fevers, bruising, infections.
    • Bleeding history: Severity, location, frequency of bleeding episodes.
    • Infection history: Types, frequency, severity of infections, response to antibiotics.
    • Constitutional symptoms: Unexplained weight loss, night sweats, anorexia.
    • Prior medical history: History of MDS, MPN, aplastic anemia.
    • Prior treatment: History of chemotherapy or radiation therapy for other cancers.
    • Medication history: Current medications, including immunosuppressants.
    • Family history: Any family history of hematologic malignancies or genetic syndromes.
    • Environmental/occupational exposures: History of exposure to benzene or other known carcinogens.
    • Travel history: To assess for infectious risks.
  • Red Flags:
    • Rapidly worsening fatigue, pallor, and dyspnea.
    • Unexplained fever with neutropenia.
    • New onset of easy bruising, petechiae, or significant bleeding (e.g., gum bleeding, epistaxis, menorrhagia).
    • Sudden onset of severe infections with minimal immune response.
    • Symptoms of leukostasis (e.g., sudden onset confusion, vision changes, dyspnea with high WBC count).

Laboratory Tests

Essential for diagnosis, classification, and risk stratification.

  • First-Line:
    • Complete Blood Count (CBC) with differential:
      • Typically shows pancytopenia (anemia, neutropenia, thrombocytopenia) or bicytopenia.
      • Presence of blasts: Circulating blasts in the peripheral blood are a hallmark. The absolute blast count can be highly variable.
      • White Blood Cell (WBC) count can be low, normal, or very high.
    • Peripheral blood smear: Microscopic examination to confirm blasts, assess morphology, and rule out other conditions.
    • Basic metabolic panel (BMP): Assess renal and electrolyte status.
    • Liver function tests (LFTs): Assess liver involvement or toxicity.
    • Lactate Dehydrogenase (LDH) and Uric Acid: Often elevated due to high cell turnover, indicating potential for tumor lysis syndrome.
    • Coagulation studies (PT, aPTT, Fibrinogen, D-dimer): Essential, especially if bleeding, to rule out DIC (critical in suspected APL).
  • Confirmatory:
    • Bone Marrow Aspiration and Biopsy: The definitive diagnostic test.
      • Morphology: Assessment of blast percentage (≥20% blasts in BM or peripheral blood is diagnostic unless specific genetic abnormalities are present), and maturation patterns of myeloid, erythroid, and megakaryocytic lineages.
      • Flow Cytometry (Immunophenotyping): Identifies surface and cytoplasmic antigens on leukemic blasts to confirm myeloid lineage and exclude lymphoid leukemia (e.g., positive for CD13, CD33, CD117, MPO, CD34; negative for CD3, CD19, CD20). Also crucial for identifying minimal residual disease (MRD) markers.
      • Cytogenetics: Karyotyping to detect chromosomal abnormalities (e.g., t(8;21), inv(16), t(15;17), monosomy 5/7, complex karyotype). Crucial for risk stratification.
      • Fluorescence In Situ Hybridization (FISH): Rapid detection of specific common translocations (e.g., PML-RARA for APL).
      • Molecular Genetics: Mutational analysis for common gene mutations (NPM1, FLT3-ITD/TKD, CEBPA, IDH1/2, TP53, ASXL1, RUNX1, SF3B1, etc.). These are critical for refined risk stratification and guiding targeted therapy.
    • Lumbar Puncture (LP): Performed if there are neurological symptoms or in specific high-risk subtypes (e.g., monocytic AML with very high WBC count) to check for CNS involvement. Contraindicated in severe thrombocytopenia unless platelets are transfused.
  • Monitoring:
    • CBC with differential: Frequently during induction and consolidation, then periodically for long-term follow-up.
    • Bone Marrow Biopsy: Performed after induction therapy to assess for remission (typically <5% blasts in a normocellular marrow). Subsequent biopsies are performed for relapse suspicion or MRD assessment.
    • Minimal Residual Disease (MRD) testing: Highly sensitive tests (multiparameter flow cytometry, PCR for specific fusion genes like PML-RARA or NPM1 mutations) used to detect residual leukemic cells after treatment, even when morphologic remission is achieved. MRD negativity correlates with better outcomes.

Imaging

Primarily used to evaluate for extramedullary disease, organ infiltration, or complications.

  • Recommended:
    • Chest X-ray (CXR): To evaluate for pulmonary infections, leukemic infiltrates, or mediastinal adenopathy.
    • Computed Tomography (CT) scan of chest, abdomen, and pelvis: To assess for organomegaly (spleen, liver), lymphadenopathy, or specific sites of infection (e.g., fungal pneumonia).
  • Advanced:
    • Magnetic Resonance Imaging (MRI) of brain/spine: If CNS involvement is suspected (e.g., neurological symptoms, positive CSF cytology).
    • PET/CT scan: Less commonly used for initial staging in AML compared to lymphoma, but can be helpful for evaluating myeloid sarcoma or unclear sites of infection.

Management

Management of AML is complex, often intensive, and requires a multidisciplinary approach involving hematologist-oncologists, pathologists, geneticists, infectious disease specialists, and supportive care teams.

Acute Management

Focused on immediate life-threatening complications and stabilizing the patient for definitive treatment.

  • Immediate (First 1-2 hours):
    • Establish IV access: Secure at least two large-bore IV lines.
    • Fluid resuscitation: Maintain hydration to prevent tumor lysis syndrome.
    • Empiric broad-spectrum antibiotics: For febrile neutropenia (fever >38.3°C with ANC <500 cells/µL). Initial regimen often includes a carbapenem (e.g., Meropenem 1g IV q8h) or an anti-pseudomonal beta-lactam (e.g., Piperacillin-Tazobactam 4.5g IV q6h).
    • Blood product support:
      • Red Blood Cell (RBC) transfusion: For symptomatic anemia (Hb typically <7-8 g/dL).
      • Platelet transfusion: For active bleeding or prophylactic for severe thrombocytopenia (platelet count <10,000/µL, or <20,000-50,000/µL if active bleeding or planned invasive procedure).
    • Manage Tumor Lysis Syndrome (TLS): Allopurinol (300 mg PO daily) or Rasburicase (0.2 mg/kg IV once or daily) for hyperuricemia. Aggressive IV fluids, monitor electrolytes (potassium, phosphate, calcium), renal function.
  • Stabilization (Early management priorities):
    • Leukostasis management: For WBC >100,000/µL with symptoms (dyspnea, altered mental status).
      • Hydroxyurea: Oral cytotoxic agent (e.g., 2-4 g/day) to rapidly lower WBC count.
      • Leukapheresis: May be considered for severe symptomatic leukostasis, but its impact on survival is debated. Chemotherapy should follow rapidly.
    • DIC management: For APL, immediately initiate All-Trans Retinoic Acid (ATRA) as soon as APL is suspected, even before confirmation, to prevent/manage DIC. Supportive care with blood products.
  • Emergency:
    • Septic shock: Aggressive fluid resuscitation, vasopressors, escalation of antibiotics.
    • CNS hemorrhage: Due to severe thrombocytopenia or leukostasis; emergency platelet transfusion, neurosurgical consultation if indicated.
    • Respiratory failure: Due to infection, hemorrhage, or leukostasis; may require ventilatory support.

Chronic Management

Refers to definitive anti-leukemic therapy and post-remission strategies.

  • Pharmacological:
    • Induction Chemotherapy (Goal: achieve complete remission (CR)):
      • Standard Intensive Induction ("7+3"): For fit patients, typically Cytarabine (100 mg/m²/day continuous IV infusion for 7 days) plus an anthracycline (Daunorubicin 60-90 mg/m²/day IV for 3 days or Idarubicin 12 mg/m²/day IV for 3 days).
      • Targeted Therapies in Induction:
        • FLT3 inhibitors: Midostaurin (80 mg PO BID) added to "7+3" for newly diagnosed FLT3-mutated AML.
        • Gemtuzumab Ozogamicin (GO): Anti-CD33 antibody-drug conjugate (e.g., 3 mg/m² IV on days 1, 4, 7) can be added to "7+3" for CD33-positive AML, particularly for favorable/intermediate risk.
        • Venetoclax (BCL-2 inhibitor) + Hypomethylating Agent (HMA): For older or unfit patients unable to tolerate intensive chemotherapy (Venetoclax 400 mg PO daily, Azacitidine 75 mg/m² SC/IV for 7 days, Decitabine 20 mg/m² IV for 5 days). This combination has significantly improved outcomes in this population.
      • For Acute Promyelocytic Leukemia (APL): All-Trans Retinoic Acid (ATRA) (45 mg/m²/day PO) plus Arsenic Trioxide (ATO) (0.15 mg/kg/day IV) is the standard of care, often with or without an anthracycline. This is distinct from other AML subtypes due to high curability and risk of DIC.
    • Consolidation Therapy (Goal: eliminate residual disease, prevent relapse): After achieving CR.
      • High-Dose Cytarabine (HiDAC): Standard for younger, fit patients, typically 3-4 cycles (e.g., Cytarabine 3 g/m² IV over 3 hours every 12 hours on days 1, 3, 5).
      • Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): Considered for intermediate-risk and adverse-risk AML patients in first complete remission, particularly those with detectable MRD. Offers the strongest anti-leukemic effect.
    • Maintenance Therapy:
      • Oral Azacitidine: Approved for patients who achieve CR/CRi after intensive induction and are not candidates for allo-HSCT, shown to prolong relapse-free and overall survival.
      • Targeted agents: Continue targeted therapies if applicable (e.g., Gilteritinib for FLT3mutated relapsed/refractory AML).
  • Non-pharmacological:
    • Supportive care: Nutrition, psychological support, social work services, rehabilitation.
    • Infection prophylaxis: Antifungal (e.g., posaconazole, voriconazole), antiviral (e.g., acyclovir, valacyclovir), and antibacterial (e.g., fluoroquinolone) prophylaxis during periods of prolonged neutropenia.
    • Blood product support: Ongoing as needed throughout treatment.
  • Monitoring:
    • Regular CBCs (daily during induction, then weekly, then monthly).
    • Repeat bone marrow biopsies to assess remission status and MRD.
    • Imaging as indicated for complications or suspected relapse.
    • Monitoring for treatment-related toxicities (e.g., cardiotoxicity from anthracyclines, neurotoxicity from cytarabine).

Treatment Algorithms

Treatment decisions are highly individualized based on patient fitness, age, and disease-specific risk factors (cytogenetics, molecular mutations).

  • First-Line Treatment Approach:
    • Fit patients (generally <60-70 years, good performance status, no major comorbidities):
      • Intensive Induction: Standard "7+3" regimen (Cytarabine + Anthracycline).
      • Post-Induction (if CR achieved):
        • Favorable-risk AML (e.g., t(8;21), inv(16), NPM1mutated without FLT3-ITD, biallelic CEBPA): Consolidation with HiDAC (3-4 cycles). Allo-HSCT reserved for relapse or if MRD becomes positive.
        • Intermediate-risk AML (e.g., normal karyotype, NPM1mutated with low-ratio FLT3-ITD): Consolidation with HiDAC or Allo-HSCT (often preferred if suitable donor available and strong evidence of benefit, especially with MRD positivity).
        • Adverse-risk AML (e.g., complex karyotype, monosomy 5/7, TP53 mutation, FLT3-ITD high allelic ratio): Allo-HSCT is the preferred consolidation strategy if CR is achieved and the patient is transplant-eligible.
    • Unfit patients (generally >70 years, poor performance status, significant comorbidities):
      • Lower-Intensity Therapy:
        • Venetoclax + Hypomethylating Agent (HMA) (Azacitidine or Decitabine) is now the preferred regimen due to superior response rates and survival compared to HMA alone.
        • HMA monotherapy: For those not candidates for Venetoclax combo.
        • Low-dose Cytarabine (LDAC): Alternative for frail patients.
        • Targeted monotherapies: Ivosidenib or Enasidenib for IDH1 or IDH2 mutated AML, respectively, if other options are unsuitable.
        • Supportive care only: For very frail patients.
  • Second-Line Treatment (Relapsed/Refractory AML):
    • Salvage Chemotherapy: Intensive regimens (e.g., FLAG-IDA: Fludarabine, High-dose Cytarabine, G-CSF, Idarubicin; or high-dose Cytarabine + Mitoxantrone) for patients who relapse or are refractory, aiming for a second remission.
    • Targeted Therapies:
      • Gilteritinib: Potent FLT3 inhibitor for relapsed/refractory FLT3-mutated AML.
      • Ivosidenib/Enasidenib: For IDH1/2 mutated relapsed/refractory AML.
      • Gemtuzumab Ozogamicin: For CD33-positive relapsed/refractory AML.
      • Venetoclax combinations: Increasingly used for relapsed/refractory disease.
    • Allogeneic HSCT: If a second remission is achieved, allo-HSCT is often pursued if not done previously, or as a second transplant in selected cases.
    • Clinical Trials: Participation in clinical trials of novel agents is highly encouraged given the poor prognosis for relapsed/refractory AML.
  • Refractory Cases:
    • Patients who fail multiple lines of therapy have very limited options.
    • Focus shifts to palliative care and symptom management to maintain quality of life.
    • Continued enrollment in early-phase clinical trials of novel agents (e.g., cellular therapies like CAR T-cells, bispecific antibodies, immune checkpoint inhibitors, next-generation targeted agents).

Complications

Complications can arise from the disease itself, its treatment, or the underlying bone marrow failure.

  • Common:
    • Febrile Neutropenia: Most frequent and life-threatening complication during chemotherapy.
    • Mucositis: Painful inflammation and ulceration of mucous membranes, especially oral and GI, due to chemotherapy.
    • Nausea, vomiting, diarrhea: Common chemotherapy side effects.
    • Fatigue: Multifactorial (anemia, disease, treatment, psychological).
    • Alopecia: Hair loss from chemotherapy.
    • Infections: Bacterial, fungal (e.g., Aspergillus, Candida), viral (e.g., CMV, HSV), due to prolonged neutropenia and immunosuppression.
  • Serious:
    • Tumor Lysis Syndrome (TLS): Metabolic derangements (hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) due to rapid lysis of leukemic cells, potentially leading to renal failure, arrhythmias, seizures.
    • Disseminated Intravascular Coagulation (DIC): Especially in APL, leading to simultaneous bleeding and clotting.
    • Leukostasis: High WBC count causing microvascular occlusion in lungs, brain, leading to respiratory failure or stroke.
    • Sepsis/Septic Shock: Life-threatening infection.
    • Cardiotoxicity: From anthracyclines (e.g., Daunorubicin, Idarubicin), potentially leading to heart failure.
    • Neurological complications: From CNS infiltration, chemotherapy-induced neurotoxicity (e.g., high-dose cytarabine), or hemorrhage.
    • Graft-versus-Host Disease (GvHD): Post-allogeneic HSCT, can be acute or chronic, affecting skin, liver, GI tract, etc.
  • Long-term:
    • Secondary malignancies: Increased risk, especially after t-AML.
    • Organ damage: Chronic cardiotoxicity, pulmonary fibrosis, renal insufficiency, hepatic complications (e.g., sinusoidal obstruction syndrome post-HSCT).
    • Infertility: Common after intensive chemotherapy and radiation.
    • Chronic fatigue and cognitive impairment: Common post-treatment sequelae.
    • Psychological distress: Anxiety, depression, PTSD.
    • Infections: Recurrent or chronic infections due to prolonged immunosuppression.

Prognosis

AML prognosis is highly variable and depends on a combination of patient and disease characteristics.

  • Factors Affecting Outcome:
    • Age: Younger patients generally have better outcomes and tolerate intensive therapy better.
    • Performance Status: Better PS correlates with better outcomes.
    • Cytogenetics/Karyotype:
      • Favorable-risk: t(8;21), inv(16) or t(16;16), PML-RARA fusion (APL).
      • Intermediate-risk: Normal karyotype, +8, other non-specific abnormalities.
      • Adverse-risk: Complex karyotype (≥3 abnormalities), monosomy 5 or 7, deletion 5q/7q, TP53 mutation.
    • Molecular Mutations:
      • Favorable: NPM1 mutation without FLT3-ITD, biallelic CEBPA mutation.
      • Adverse: High allelic ratio FLT3-ITD, TP53 mutation, ASXL1, RUNX1, EZH2.
    • Initial WBC count: Very high WBC (>100,000/µL) associated with poorer prognosis due to risk of leukostasis.
    • Secondary AML: AML arising from MDS/MPN or prior therapy generally has a worse prognosis.
    • Response to Induction: Failure to achieve complete remission after one cycle.
    • Minimal Residual Disease (MRD): MRD negativity after consolidation is a strong predictor of durable remission and better survival.
  • Survival:
    • Overall 5-year survival for adults with AML is approximately 30-40%.
    • For younger, fit patients with favorable-risk disease, 5-year survival rates can exceed 70%.
    • For older patients or those with adverse-risk disease, 5-year survival rates can be less than 20-30%.
    • APL has a significantly better prognosis, with 5-year survival rates often >80-90% with ATRA/ATO therapy.
  • Quality of Life:
    • Significantly impacted during intensive treatment due to physical and psychological burdens.
    • Long-term survivors may experience chronic fatigue, cognitive impairment, emotional distress (anxiety, depression), and organ toxicities related to treatment.
    • Survivorship care is increasingly important to address long-term sequelae and improve quality of life.

Prevention

Primary prevention of AML is largely limited, but secondary and tertiary prevention efforts are crucial.

  • Primary Prevention:
    • Avoid known carcinogens: Minimize exposure to chemicals like benzene (e.g., in industrial settings) and high-dose radiation.
    • Manage pre-malignant conditions: Close monitoring and appropriate management of myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) may reduce progression to AML, though this is not always preventable.
    • Healthy lifestyle: General health promotion, though no specific dietary or lifestyle interventions are proven to prevent AML.
  • Secondary Prevention:
    • Early detection: No routine screening tests for AML exist for the general population. Secondary prevention relies on prompt recognition and evaluation of symptoms (e.g., persistent fatigue, unexplained fevers, easy bruising) that may suggest AML, leading to early diagnosis and initiation of treatment.
    • Genetic counseling: For individuals with a family history of specific genetic syndromes predisposing to AML.
  • Tertiary Prevention:
    • Preventing complications: Proactive management of neutropenia, thrombocytopenia, and TLS during treatment.
    • Managing long-term effects: Regular screening for late effects of chemotherapy (e.g., cardiac function, endocrine dysfunction, secondary cancers).
    • Psychosocial support: Addressing the mental health needs of survivors.
    • Rehabilitation: Physical and occupational therapy to address treatment-related deconditioning and improve functional outcomes.

Special Populations

Management strategies are often modified for specific patient groups.

  • Pediatric:
    • AML in children is rare (approx. 20% of childhood leukemias).
    • Different epidemiology and biology: certain genetic abnormalities are more common (e.g., KMT2A rearrangements, NUP98-NSD1), and prognoses can differ from adults.
    • Treatment protocols are highly specialized (e.g., Children's Oncology Group [COG] protocols) and often involve more intensive chemotherapy regimens.
    • Long-term side effects are a major concern given longer life expectancy.
  • Geriatric:
    • AML is predominantly a disease of the elderly, but older patients often have more comorbidities, poorer performance status, and unfavorable disease biology (e.g., secondary AML, adverse cytogenetics, TP53 mutations).
    • Tolerance to intensive chemotherapy is reduced.
    • Management often favors lower-intensity regimens (e.g., Venetoclax + HMA) or targeted therapies, balancing efficacy with toxicity and quality of life.
    • Individualized risk-benefit assessment is paramount.
  • Pregnancy:
    • AML during pregnancy is very rare.
    • Diagnosis can be challenging due to physiological changes mimicking symptoms (e.g., anemia, thrombocytopenia).
    • Treatment decisions require careful consideration of maternal and fetal risks. Chemotherapy is generally avoided in the first trimester due to teratogenicity. In the second or third trimester, intensive chemotherapy may be considered if maternal life is at risk, with specific agents chosen for lower fetal toxicity. Delivery may be induced if the fetus is viable. APL requires immediate ATRA.
  • Comorbidities:
    • Cardiac dysfunction: Anthracycline doses may need to be reduced or alternative agents used in patients with pre-existing heart failure or significant cardiac risk factors.
    • Renal/Hepatic impairment: Dosing adjustments for renally or hepatically cleared drugs are often necessary.
    • Infections: Patients with chronic infections (e.g., hepatitis B/C, HIV) require careful monitoring and proactive management.
    • Other chronic conditions: Diabetes, chronic lung disease, etc., require careful management during intensive treatment.

Clinical Pearls

  • Diagnostic:
    • Always suspect AML in an adult patient with rapid onset of unexplained fatigue, fever, and/or bleeding, especially if a CBC reveals pancytopenia with blasts or isolated profound cytopenias.
    • Bone marrow biopsy is the cornerstone of diagnosis and essential for comprehensive risk stratification (morphology, flow cytometry, cytogenetics, molecular). Peripheral blood blast count ≥20% is often sufficient for provisional diagnosis, but BM confirmation is critical for full characterization.
    • Do not delay APL treatment: If acute promyelocytic leukemia (APL) is suspected (e.g., pancytopenia with prominent promyelocytes and DIC), initiate All-Trans Retinoic Acid (ATRA) immediately, even before genetic confirmation of PML-RARA, to prevent life-threatening coagulopathy.
  • Treatment:
    • Risk stratification drives therapy: Cytogenetic and molecular findings dictate the intensity and type of post-remission therapy (HiDAC vs. Allo-HSCT) and the use of targeted agents.
    • Early and aggressive supportive care is paramount: Proactive management of febrile neutropenia, bleeding, and tumor lysis syndrome can be life-saving.
    • Consider patient fitness, not just age: Age cutoffs are guidelines. A fit 75-year-old may tolerate intensive therapy better than a frail 60-year-old. Comprehensive geriatric assessment is valuable.
    • MRD assessment is crucial: MRD negativity predicts better outcomes and can guide decisions on allo-HSCT or maintenance therapy.
  • Pitfalls:
    • Misdiagnosing AML as other conditions: AML symptoms are often non-specific and can be confused with severe infections, aplastic anemia, or other myelodysplastic conditions. A high index of suspicion is needed.
    • Delaying diagnosis: Rapid progression can occur, making prompt diagnosis critical.
    • Inadequate supportive care: Failure to manage neutropenic fever, bleeding, or metabolic derangements can lead to early mortality.
    • Overlooking CNS involvement: Although rare at presentation, CNS prophylaxis or evaluation is important in specific high-risk subsets (e.g., high WBC monocytic AML).
    • Failure to test for all relevant mutations: Missing key mutations (e.g., FLT3, IDH1/2, NPM1) can lead to suboptimal therapeutic decisions, especially with the increasing availability of targeted therapies.

Recent Updates

  • Guidelines:
    • WHO Classification (2022 revision): Incorporates new genetic entities and refines criteria for existing categories, emphasizing the role of molecular markers in diagnosis and prognosis.
    • European LeukemiaNet (ELN) 2022 Recommendations: Updated risk stratification based on cytogenetics and molecular mutations (NPM1, FLT3-ITD, CEBPA, TP53, ASXL1, RUNX1, SF3B1), guiding post-remission therapy.
    • NCCN Guidelines for AML: Continuously updated to reflect the latest evidence and integrate new targeted therapies and management strategies.
  • Evidence:
    • Integration of Venetoclax: The combination of Venetoclax with HMAs (Azacitidine or Decitabine) has become the new standard of care for newly diagnosed AML in older/unfit patients, demonstrating significantly improved response rates and survival compared to HMA monotherapy.
    • FLT3 inhibitors: Midostaurin added to "7+3" for FLT3-mutated AML in induction, and Gilteritinib as a highly effective agent for relapsed/refractory FLT3-mutated AML.
    • IDH inhibitors: Ivosidenib (IDH1) and Enasidenib (IDH2) have demonstrated efficacy in both newly diagnosed (for unfit patients) and relapsed/refractory AML with these specific mutations.
    • Oral Azacitidine: Approved for maintenance therapy in patients who achieved CR/CRi with intensive chemotherapy and are not eligible for allo-HSCT, showing prolonged relapse-free and overall survival.
    • Improved MRD testing: More sensitive and standardized methods for MRD detection provide better prognostic information and may guide treatment intensity.
  • Controversies:
    • Optimal induction for fit older adults: Balancing intensive "7+3" with Venetoclax + HMA, especially in the "fit elderly" subset where toxicity concerns exist.
    • Role of MRD in guiding consolidation: While MRD negativity is prognostic, its role in directly de-escalating or escalating therapy (e.g., deciding against allo-HSCT in MRD-negative intermediate-risk AML) is still being refined and may vary by specific MRD assay and risk group.
    • Optimal maintenance duration and strategy: The precise role and duration of maintenance therapies are still under active investigation.

Key References

  • Guidelines:
    • Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140(12):1345-1377. (European LeukemiaNet guidelines, essential for risk stratification)
    • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Accessed via NCCN.org). (Frequently updated, comprehensive guidelines for diagnosis and treatment)
    • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. (For classification criteria, awaiting widely adopted 2022 updates).
    • Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719. (Key reference for the newest classification)
  • Studies:
    • Tallman MS, et al. Midostaurin in Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377(10):971-972. (RATIFY trial, pivotal for Midostaurin in FLT3-AML).
    • DiNardo CD, et al. Venetoclax combined with Azacitidine in untreated acute myeloid leukemia: results from a phase 1b study. Blood. 2018;132(S1):683. (Seminal study for Venetoclax + HMA).
    • Wei AH, et al. Venetoclax plus Azacitidine in Previously Untreated AML: Long-Term Survival and Molecular Remission Outcomes from the VIALE-A Study. Blood. 2021;138(Suppl 1):691. (Key update for Venetoclax + HMA in unfit AML).
    • Wei AH, et al. Oral azacitidine maintenance in older patients with AML in first remission. N Engl J Med. 2020;383(26):2526-2537. (QL-AML-001 trial, pivotal for oral Azacitidine maintenance).
  • Reviews:
    • Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907. (Classic review on AML).
    • Papaemmanuil E, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-2221. (Detailed review on molecular landscape).
    • Short NJ, et al. Acute Myeloid Leukemia: A Review of the Biology and Treatment Paradigms. J Natl Compr Canc Netw. 2018;16(5):610-621. (Comprehensive review).

Dr. Vivek's AI | For Educational Purposes Only